BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37453678)

  • 1. Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database.
    Perrier M; Mouawad C; Gueguen D; Thomé B; Lapeyre-Mestre M; Walter T
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102177. PubMed ID: 37453678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
    Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
    Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.
    Broder MS; Chang E; Romanus D; Cherepanov D; Neary MP
    World J Gastroenterol; 2016 Feb; 22(6):2118-25. PubMed ID: 26877616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare cost by primary tumour, functioning status and treatment among patients with metastatic neuroendocrine tumours: The LyREMeNET study.
    Perrier M; Polazzi S; Lemelin A; Fernandez V; Labonne S; Maucort-Boulch D; Lombard-Bohas C; Duclos A; Walter T
    J Neuroendocrinol; 2022 Apr; 34(4):e13092. PubMed ID: 35078272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.
    Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Gomez MJ; Del Olmo-García MI; Lorenzo I; Díaz JÁ; Canal N; De la Cruz G; Villabona C
    Clin Transl Oncol; 2021 Oct; 23(10):2046-2056. PubMed ID: 34109562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
    Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
    Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct costs of carcinoid syndrome diarrhea among adults in the United States.
    Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
    World J Gastroenterol; 2019 Dec; 25(47):6857-6865. PubMed ID: 31885426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.
    Shen C; Chu Y; Halperin DM; Dasari A; Zhou S; Xu Y; Yao JC; Shih YT
    Oncologist; 2017 Dec; 22(12):1451-1462. PubMed ID: 28642335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
    Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
    Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in the Diagnosis and Management of Carcinoid Syndrome.
    Subash N; Papali MM; Bahadur KP; Avanthika C; Jhaveri S; Thannir S; Joshi M; Valisekka SS
    Dis Mon; 2022 Jul; 68(7):101304. PubMed ID: 34972546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
    Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
    J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-A population-based register-linkage study.
    Lesén E; Granfeldt D; Houchard A; Berthon A; Dinet J; Gabriel S; Björstad Å; Björholt I; Elf AK; Johanson V
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12983. PubMed ID: 30652364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.
    Broder MS; Cai B; Chang E; Yan T; Benson AB
    J Med Econ; 2018 Aug; 21(8):821-826. PubMed ID: 29741466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States.
    Burton T; Lapuerta P
    Future Oncol; 2018 Oct; 14(23):2361-2370. PubMed ID: 30095284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors.
    Cai B; Broder MS; Chang E; Yan T; Metz DC
    World J Gastroenterol; 2017 Oct; 23(40):7283-7291. PubMed ID: 29142475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
    Kostiainen I; Karppinen N; Simonen P; Rosengård-Bärlund M; Lindén R; Tarkkanen M; Gordin D; Rapola J; Schalin-Jäntti C; Matikainen N
    Endocrine; 2022 Jun; 77(1):177-187. PubMed ID: 35536452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USA.
    Broder MS; Cai B; Chang E; Yan T; Benson Iii AB
    Curr Med Res Opin; 2018 Dec; 34(12):2151-2156. PubMed ID: 30047289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.